Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to -$2.9 million.

  • BioRestorative Therapies' Cash from Operations fell 7063.28% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.7 million, marking a year-over-year decrease of 4387.12%. This contributed to the annual value of -$8.2 million for FY2024, which is 2799.5% down from last year.
  • As of Q3 2025, BioRestorative Therapies' Cash from Operations stood at -$2.9 million, which was down 7063.28% from -$2.7 million recorded in Q2 2025.
  • BioRestorative Therapies' Cash from Operations' 5-year high stood at -$629364.0 during Q3 2021, with a 5-year trough of -$2.9 million in Q3 2025.
  • Moreover, its 5-year median value for Cash from Operations was -$1.6 million (2022), whereas its average is -$1.7 million.
  • As far as peak fluctuations go, BioRestorative Therapies' Cash from Operations tumbled by 13065.44% in 2022, and later skyrocketed by 1875.36% in 2023.
  • Quarter analysis of 5 years shows BioRestorative Therapies' Cash from Operations stood at -$1.1 million in 2021, then tumbled by 41.11% to -$1.6 million in 2022, then rose by 1.72% to -$1.6 million in 2023, then tumbled by 47.85% to -$2.3 million in 2024, then decreased by 23.52% to -$2.9 million in 2025.
  • Its Cash from Operations stands at -$2.9 million for Q3 2025, versus -$2.7 million for Q2 2025 and -$2.8 million for Q1 2025.